鼻内接种BECC470佐剂VLP-RBD疫苗使K18-hACE2小鼠获得抗Delta SARS-CoV-2攻击的免疫力
研究利用乙肝表面抗原病毒样颗粒(VLP)连接受体结合域(RBD)抗原,搭配TLR4激动剂佐剂BECC470制成鼻内疫苗,在K18-hACE2小鼠中于第0周和第4周初免加加强,并与mRNA-1273比较。两种疫苗均诱导血清RBD特异性IgA并保护小鼠免受致死剂量Delta变异株攻击,VLP-RBD-BECC在鼻洗液和肺上清中IgA更高、早期肺部炎症更轻,但攻击前IgG、RBD-ACE2结合抑制和体外中和活性略低于mRNA-1273。
要点
- VLP-RBD-BECC与mRNA-1273均诱导血清RBD特异性IgA,前者鼻洗液和肺上清IgA最高。
- 两种疫苗均保护K18-hACE2小鼠免受致死剂量Delta变异株攻击并限制肺部病毒复制。
- VLP-RBD-BECC鼻内接种在早期时间点限制肺部炎症,而mRNA-1273接种未显示此效果。
核心结论
- 基于VLP并搭配BECC佐剂的疫苗可用于诱导针对SARS-CoV-2的保护性黏膜和全身免疫应答。
研究设计与样本
- 研究使用乙肝表面抗原病毒样颗粒(VLP)连接受体结合域(RBD)抗原,搭配TLR4激动剂佐剂BECC470。
- K18-hACE2小鼠以四周间隔初免和加强,分别接种VLP-RBD-BECC或mRNA-1273。
主要发现
- VLP-RBD-BECC和mRNA-1273接种均使血清产生RBD特异性IgA抗体。
- 鼻洗液和肺上清中检测到RBD特异性IgA,且在VLP-RBD-BECC接种小鼠中最高。
- VLP-RBD-BECC接种小鼠攻击前IgG应答水平略低于mRNA-1273接种小鼠,RBD-ACE2结合抑制降低,体外中和活性更低。
- VLP-RBD-BECC和mRNA-1273接种小鼠均受到保护,免受致死剂量Delta变异株SARS-CoV-2攻击。
- 两种疫苗均限制小鼠肺内病毒复制和病毒RNA载量,并限制血清和肺CXCL10表达。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As the COVID-19 pandemic transitions into endemicity, seasonal boosters are a plausible reality across the globe. We hypothesize that intranasal vaccines can provide better protection against asymptomatic infections and more transmissible variants of SARS-CoV-2. To formulate a protective intranasal vaccine, we utilized a VLP-based platform. Hepatitis B surface antigen-based virus like particles (VLP) linked with receptor binding domain (RBD) antigen were paired with the TLR4-based agonist adjuvant, BECC 470. K18-hACE2 mice were primed and boosted at four-week intervals with either VLP-RBD-BECC or mRNA-1273. Both VLP-RBD-BECC and mRNA-1273 vaccination resulted in production of RBD-specific IgA antibodies in serum. RBD-specific IgA was also detected in the nasal wash and lung supernatants and were highest in VLP-RBD-BECC vaccinated mice. Interestingly, VLP-RBD-BECC vaccinated mice showed slightly lower levels of pre-challenge IgG responses, decreased RBD-ACE2 binding inhibition, and lower neutralizing activity in vitro than mRNA-1273 vaccinated mice. Both VLP-RBD-BECC and mRNA-1273 vaccinated mice were protected against challenge with a lethal dose of Delta variant SARS-CoV-2. Both vaccines limited viral replication and viral RNA burden in the lungs of mice. CXCL10 is a biomarker of severe SARS-CoV-2 infection and we observed both vaccines limited expression of serum and lung CXCL10. Strikingly, VLP-RBD-BECC when administered intranasally, limited lung inflammation at early timepoints that mRNA-1273 vaccination did not. VLP-RBD-BECC immunization elicited antibodies that do recognize SARS-CoV-2 Omicron variant. However, VLP-RBD-BECC immunized mice were protected from Omicron challenge with low viral burden. Conversely, mRNA-1273 immunized mice had low to no detectable virus in the lungs at day 2. Together, these data suggest that VLP-based vaccines paired with BECC adjuvant can be used to induce protective mucosal and systemic responses against SARS-CoV-2.
引用
- Lee KS, Rader NA, Miller-Stump OA, et al. Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice. Vaccine. 2023. PMID: 37407405. doi:10.1016/j.vaccine.2023.06.080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。